Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5873_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Acknowledgements
- •Contents at a glance
- •Contents in full
- •Abbreviations
- •Clinical clerking abbreviations
- •2.1 Agonists and antagonists: drugs acting at receptors
- •1.2 So, what is pharmacology?
- •1.3 How to use this book
- •1.4 Comment for instructors
- •1.5 Online Resource Centre
- •2.2 How receptor activation changes cells
- •2.3 Ion channels as drug targets
- •2.4 Enzymes as drug targets
- •2.5 Transporter proteins as drug targets
- •3.1 The core principles of pharmacokinetics: ADME
- •3.2 Drug elimination: clearance
- •3.3 Volume of distribution
- •3.4 Half-life of a drug
- •3.5 Absorption and bioavailability
- •4.2 Drugs used in the treatment of thromboembolic disorders
- •WORKBOOK 1
- •5.1 The physiological control of arterial blood pressure
- •5.2 Antihypertensive drugs
- •5.3 Strategies for the drug treatment of hypertension
- •WORKBOOK 2
- •6.2 Atherosclerosis
- •6.3 Preventing atherosclerosis: lipid-lowering drugs
- •6.4 Ischaemic heart disease: angina
- •6.5 Ischaemic heart disease: myocardial infarction (MI)
- •WORKBOOK 3
- •7.1 Arrhythmias
- •7.2 Anti-arrhythmic drugs
- •7.4 Chronic heart failure
- •7.5 Drugs used in heart failure
- •WORKBOOK 4
- •8.1 Structure and physiology of the skin
- •8.2 Medication for topical application to the skin
- •8.3 Eczema/dermatitis
- •8.4 Treatment of dermatitis
- •8.5 Psoriasis
- •8.6 Treatment of psoriasis
- •8.7 Acne
- •8.8 Drug treatment of acne
- •8.9 Other dermatological conditions
- •WORKBOOK 5
- •9.1 What is rheumatoid arthritis?
- •9.2 Treatment of rheumatoid arthritis
- •9.4 Disease-modifying anti-rheumatic drugs (DMARDs)
- •9.5 Cytokine blockers: biological DMARDs
- •9.6 Choice of treatment for rheumatoid arthritis
- •WORKBOOK 6
- •10.1 Allergic rhinitis
- •10.2 Treatment of allergic rhinitis
- •10.3 Urticaria
- •10.4 Treatment and management of urticaria
- •WORKBOOK 7
- •11.1 Organization of the respiratory system
- •11.2 Common airway diseases: asthma and chronic obstructive pulmonary disease (COPD)
- •11.3 Asthma
- •11.4 Treating asthma
- •11.5 Chronic obstructive pulmonary disease (COPD)
- •WORKBOOK 8
- •12.1 Structure of the gastrointestinal wall
- •12.2 The stomach
- •12.3 Disorders of the upper gastrointestinal tract
- •12.5 Nausea and vomiting
- •12.6 Antiemetic therapy
- •WORKBOOK 9
- •13.1 The lower gastrointestinal tract
- •13.2 Diarrhoea
- •13.3 Constipation
- •13.4 Irritable bowel syndrome
- •WORKBOOK 10
- •14.1 Control of blood glucose levels
- •14.2 Diabetes mellitus
- •14.3 Complications of diabetes
- •14.4 Diagnosis of diabetes
- •14.5 Drug treatment of diabetes mellitus
- •14.6 Management of diabetes
- •14.7 Obesity
- •14.8 Management of obesity
- •WORKBOOK 11
- •15.1 The thyroid gland
- •15.2 Thyroid dysfunction
- •15.3 Contraception
- •15.4 Pharmacological methods of contraception
- •WORKBOOK 12
- •16.2 The biological basis of epilepsy: brakes and accelerators
- •16.3 Three mechanisms in the drug treatment of epilepsy
- •16.4 Drugs used in the treatment of epilepsy
- •16.5 Strategy and side effects in the drug treatment of epilepsy
- •WORKBOOK 13
- •17.1 Symptoms and diagnosis of Parkinson’s disease
- •17.2 Neurodegeneration: selective death of brain neurons
- •17.3 Drug treatment of Parkinson’s disease
- •17.4 Symptoms and diagnosis of Alzheimer’s disease: a brief comment
- •17.5 Drug treatment of Alzheimer’s disease
- •WORKBOOK 14
- •18.2 Drugs in clinical use for the treatment of schizophrenia
- •18.1 What is schizophrenia? Symptoms, diagnosis, and causes
- •WORKBOOK 15
- •19.1 Depression

SUMMARY OF DRUGS USED FOR GASTRIC ULCERS AND GASTRO-OESOPHAGEAL REFLUX DISEASE
322 Chapter 12 Upper gastrointestinal tract disorders
Therapeutic class Drugs Mechanism of action Common clinical uses Comments Common adverse drug
reactions
Antacids Magnesium and aluminium
H2-receptor
antagonists
Proton pump
inhibitors
Prostaglandin
analogues
Cytoprotective
agents
Antibiotics Amoxicillin
hydroxide combinations
Ranitidine
Famotidine
Cimetidine
Nizatidine
Omeprazole
Esomeprazole
Pantoprazole
Rabeprazole
Lansoprazole
Misoprostol Mimics effects of protective
Bismuth chelate Mode of action unclear
Sucralfate Forms a physical barrier by
Clarithromycin
Metronidazole
Reduce acidity of the stomach
through neutralization
Competitive antagonist at H2
receptor
Irreversible inhibition of proton
pump (H+/K+-ATPase)
prostaglandins to increase
mucus and bicarbonate
production and decrease acid
secretion
Precipitated bismuth may coat
damaged area by binding to
exposed glycoproteins
Antibacterial action through
disruption of outer membrane
proteins
binding to exposed
glycoproteins or proteins in
damaged area
Used in triple therapy for eradication of H. pylori. See Drug summary table in Chapter 22
Dyspepsia Chelate some drugs to reduce
Gastric and duodenal ulcer
Gastro-oesophageal reflux
disease
Gastric and duodenal ulcer
Gastro-oesophageal reflux
disease
Zollinger–Ellison syndrome
H. pylori eradication
Gastric and duodenal ulcer Contraindicated in pregnancy as
Gastric and duodenal ulcer
H. pylori eradication
Gastric and duodenal ulcer Constipation
their absorption
Sometimes contains
simethicone/dimethicone
May reduce absorption of drugs
that require an acidic
environment
Cimetidine inhibits cytochrome
P450 enzymes, leading to
interactions
May reduce absorption of drugs
requiring acidic environment for
absorption
uterine contraction can induce
labour
Added to triple therapy in
H. pylori eradication when
standard triple therapy has failed
Diarrhoea (magnesium)
Constipation (aluminium)
Diarrhoea
Dizziness
Headache
Gynaecomastia
(cimetidine)
GI disturbances
Headache
Dizziness
Diarrhoea
Abdominal pain
Dizziness
Menorrhagia
Nausea and vomiting
Blackens faeces and tongue
Back pain
Bezoar formation (obstruction
in the stomach)

SUMMARY OF DRUGS USED FOR NAUSEA AND VOMITING
12.6 Antiemetic therapy 323
Therapeutic class Drugs Mechanism of action Common clinical uses Comments Common adverse drug
reactions
First-generation
antihistamines
Antimuscarinics Hyoscine hydrobromide Blocks muscarinic receptors (including
Dopamine receptor
antagonists
Selective 5-HT3
receptor antagonists
Neurokinin receptor
antagonists
Cinnarizine
Cyclizine
Promethazine
Diphenhydramine
First-generation
antipsychotics:
Chlorpromazine
Droperidol
Haloperidol
Levomepromazine
Metoclopramide
Domperidone
Ondansetron
Dolasetron
Granisetron
Palonosteron
Tropisetron
Aprepitant,
Fosaprepitant
Competitive antagonists at the H1
receptor
those involved in transmission
between inner ear and emesis centre)
Antagonist at D2 dopamine receptors
in chemoreceptor trigger zone
Block additional receptors, including
serotonin (5-HT2), histamine (H1), and
muscarinic (M1) receptors
D2 dopamine receptor antagonists
(Greater selectivity for D2 receptors
than first-generation antipsychotics)
Antagonists at 5-HT3 receptor in GI
tract and CTZ
Block actions of substance P through
antagonism of neurokinin-1 receptors
in CTZ and emesis centre
See Drug summary table in Chapter 10
Motion sickness
Vertigo
Hypersalivation
Nausea and vomiting
Psychoses
Intractable hiccup
Choreas
Nausea and vomiting
(particularly that induced by
chemotherapy or
radiotherapy)
Gastro-oesophageal reflux
disease
Motility stimulant
Nausea and vomiting
Motility stimulant
Nausea and vomiting
associated with
chemotherapy
Available as transdermal
patch
Levomepromazine has
additional analgesic
properties
Promote acetylcholine release
in myenteric plexus,
enhancing peristalsis
(prokinetic action)
Domperidone does not cross
blood–brain barrier, so has
fewer CNS side effects,
including less sedation
Superior for highly
emetogenic chemotherapy/
post surgery
Fosaprepitant is a pro-drug of
aprepitant
It reduces metabolism of
dexamethasone and
methylprednisolone
Dry mouth
Blurred vision
Urinary retention
Constipation
Sedation
Hypotension
When use is prolonged,
extrapyramidal effects:
Acute dystonia (abnormal
movements), tardive dyskinesia
(involuntary movement of tongue,
jaw and lips), and parkinsonism
(see Chapter 17)
Metoclopramide:
Sedation
Extrapyramidal effects (as
above)
Gynaecomastia
Menstrual changes
Domperidone:
Drowsiness
Dry mouth
Malaise
Constipation
Headache
Flushing
Dizziness
Anorexia
Severe fatigue
Constipation
Diarrhoea
CNS, central nervous system; GI, gastrointestinal; CTZ, chemoreceptor trigger zone.

WORKBOOK 9
Gastric ulcers and gastro-oesophageal
reflux disease
Dr Carter Brown: a simplified case history
After a short stay in accident and emergency, Dr Carter Brown is being wheeled to the
gastrointestinal ward at Glenfield Hospital.
He has been brought into hospital by his mother, who was shocked by his appearance when
she had called in to see him. She has been keeping an eye on him since his recent divorce,
which hit him hard. She is worried about the number of takeaways he has been having, and she
thinks he has definitely been drinking too much.
She was horrified to find him lying on the sofa, clutching his stomach in obvious agony. He had
then been violently sick. The appearance of the vomit, which looked like coffee grounds,
alarmedthemboth,andCarterrealizedhewasmoreillthanhehadadmitted.
He felt too ill to protest when his mother bundled him into the car and drove him to hospital,
although he was uncomfortable with the idea of being a patient in the hospital where he used to
work.
A table of clinical clerking abbreviations is given on page xviii.
CLINICAL CLERKING FOR DR CARTER BROWN AT ACCIDENT
AND EMERGENCY DEPARTMENT
Age: 35 years
PC: Gnawing abdominal pain accompanied by vomit with the appearance of coffee grounds
The appearance of the vomit indicates the presence of blood that has coagulated in the gastric juices.
HPC: Intermittent stomach pains over 2 days, gradually becoming more severe. Similar, though not
as severe, pains over the last 6 months. Initially tried over-the-counter antacids. Following diagnosis
of gastro-oesophageal reflux disease, received medication, which helped until current episode. Since
yesterday, he has had several dark-coloured, very loose bowel movements.
PMH:
Gastro-oesophageal reflux disease
Recent injury sustained in a domestic incident
Before the diagnosis of gastro-oesophageal reflux disease, Dr Brown had not had any significant
illness

WORKBOOK 9 Gastric ulcers and gastro-oesophageal reflux disease 325
DH:
1) Ranitidine for gastro-oesophageal reflux disease
2) Ibuprofen (prescribed for a recent injury)
3) Gaviscon®: occasionally
Until recently his gastro-oesophageal reflux disease has been controlled by ranitidine, and occasional
doses of Gaviscon®. Since starting ibuprofen for an acute injury, his symptoms have no longer been
controlled
SH: 35-year-old medical doctor. Recently divorced, he lives alone. Smokes 20 cigarettes a day and
drinks about 30 units of alcohol per week.
Smoking impairs ulcer healing and promotes recurrence. Alcohol and stress are implicated as
predisposing factors in peptic ulcer disease.
O/E:
1) Pale, sweating, and shocked
2) Blood pressure = 115/60 mmHg (ideal: <140/90 mmHg)
3) Pulse = 98 beats per minute (normal: 60 beats/min)
Diarrhoea and vomiting have led to significant loss of fluids which has resulted in signs of shock
(pale sweaty skin, low blood pressure, and a raised pulse).
4) Abdomen = tender
5) Rectal examination = melaena
Melaena: passage of black tarry faeces, a result of bleeding into the upper gastrointestinal tract.
6) Weight = 120 kg
7) Height = 185 cm
Carter is overweight. Excess weight is a risk factor for gastro-oesophageal reflux disease.
Biochemistry:
All within range except:
1) Haemoglobin = 10 g/dl (reference: male 13.5–17 g/dl; female 11.5–15 g/dl)
2) Mean cell volume = 72 fl (reference 80–90 fl)
3) Haematocrit = 31% (reference male 39–50%; female 36–44%)
Haemoglobin level is the most commonly used index for detecting anaemia (defined as a lower than
normal O2-carrying capacity of the blood). The loss of blood due to gastric bleeding has resulted in
iron-deficiency anaemia.
Mean cell volume is the average volume of a red blood cell (erythrocyte). Where this is low a
diagnosis of microcytic anaemia is made, as seen in iron-deficient states.
Haematocrit: the proportion of blood volume occupied by all blood cells. As more than 99% of the
cells are erythrocytes, this index essentially represents the proportion of blood volume occupied by
erythrocytes. This value is low in all forms of anaemia.
Together these three readings indicate that Carter has iron-deficiency anaemia as a result of gastric
bleeding.
Provisional diagnosis: Gastric ulcer

326 Chapter 12 Upper gastrointestinal tract disorders
Plan:
• Halfhourlyobservations
• Endoscopy
• [13C] Urea breath test
• Intravenousuids
• Ranitidine
• Metoclopramide,asrequired
• Ferroussulfate
• Discontinueibuprofen
1) Endoscopy: A procedure using a flexible tube with a light source and camera. The tube is inserted
through the mouth and enables visualization of the oesophagus, stomach, and duodenum.
2) [13C] or [14C]Urea breath test is used to detect Helicobacter pylori infection. This test depends on
the conversion of urea by bacterial urease enzymes into ammonia and CO2. The patient is given
urea labelled with a carbon isotope. Where infection is present, labelled CO2 is excreted in the
patient’s breath and can be detected.
3) Metoclopramide: a D2 dopamine receptor antagonist which targets receptors in the
chemoreceptor trigger zone to control vomiting.
4) Ferrous sulfate: to correct anaemia resulting from blood loss, and replenish the body’s iron
stores.
5) Carter must stop taking the non-steroidal anti-inflammatory drug ibuprofen. This class of drug
can cause peptic ulcers through inhibition of prostaglandin production. Prostaglandins,
particularly PGE2, have beneficial protective properties in the gastric mucosa.
Although it is late, Carter’s mum insists on staying with him while they wait for the doctors. She
is worried, and cannot understand why her son is so sick.
1) List and explain five ways in which the stomach protects itself against the actions of gastric juices.
2) Name two substances found in the stomach that would destroy the mucosa in the absence of the
protective features mentioned above.
3a) Name the three main endogenous signals which promote acid secretion by parietal cells.
3b) How do they change parietal cell function?
The gastroenterologist finally comes to see Carter.
Although he knows Carter is a doctor, he explains both to him and his mum what he believes
theproblemtobe.Carter’smumispuzzledasshelistenstohimtalkaboutpumpsand
prostaglandins.
4a) What is the name of the pump involved in the secretion of acid by the parietal cell?
4b) What is the source of the protons (H+ ) transported by this pump?

WORKBOOK 9 Gastric ulcers and gastro-oesophageal reflux disease 327
The doctor considers it likely that a combination of factors has contributed to Carter developing
an ulcer; the results of tests to confirm this diagnosis are pending. The doctor talks about
mucosal damage, and a lack of mucosal protection. Carter and the gastroenterologist discuss
his use of the non-steroidal anti-inflammatory drug ibuprofen.
5) What are the two most common causes of peptic ulcers?
6) Explain how taking ibuprofen may have contributed to the development of a peptic ulcer in Carter’s case.
7a) What is Helicobacter pylori?
7b) Explain how H. pylori infection can lead to the formation of a peptic ulcer.
Carter has been given metoclopramide to help prevent vomiting.
8a) Explain the mechanism of action of metoclopramide in preventing vomiting.
8b) Is there another action of metoclopramide which may benefit Carter?
8c) What are the main side effects of metoclopramide, and which groups of patients are most likely to
be affected?
The doctor asks Carter about his symptoms of gastro-oesophageal reflux disease.
9) What is gastro-oesophageal reflux disease, and what are its usual symptoms?
10) What is the main objective in the treatment of gastro-oesophageal reflux disease?
Carter informs the gastroenterologist that he was prescribed ranitidine by his GP for his symptoms.
11a) What class of drug does ranitidine belong to?
11b) How does this drug act to reduce symptoms of gastro-oesophageal reflux disease?
The doctor tells Carter that if the test results for H. pylori infection are positive, he will be
prescribed a combination of drugs instead of ranitidine.
They expect the results within an hour. Carter is encouraged to rest. The gastroenterologist
has to leave, but he tells Carter that another doctor from his team will come round later to
explain the results.
Carter’s mum finally agrees to go home, after being reassured that she can phone at any time to
find out how he is.
Two hours later Carter almost passes out when he is woken up by his ex-wife, Dr Knight, who is
now on the gastroenterology team. She acts very professionally and explains that the
endoscopy has confirmed an ulcer and that the urea breath test has detected H. pylori infection.

328 Chapter 12 Upper gastrointestinal tract disorders
She explains to Carter that he will be given triple therapy to eradicate H. pylori, and to promote
healingoftheulcer.Thiswillconsistofaprotonpumpinhibitor,lansoprazole,andtwo
antibiotics, clarithromycin and amoxicillin.
12) Explain the rationale for triple therapy in the treatment of gastric ulcers where H. pylori is detected.
13) Explain the mechanism of action of proton pump inhibitors.
14) Why do proton pump inhibitors decrease stomach acidity more effectively than histamine H2
receptor antagonists?
DrKnighttellsCarterthatowingtothesizeofhisulcerhewillhavetostayinhospital.She
leaves after discussing Carter’s medication with the nurses.
Carter is unhappy about having to stay in hospital. To make matters worse, the triple therapy
fails to eradicate the H. pylori infection after 7 days.
Thedrugcombinationischangedtolansoprazole,bismuthchelate,amoxicillin,and
metronidazole.
15) Explain the action of bismuth chelate in H. pylori-induced peptic ulcer.
After one week on this combination, Carter finally gets better and is able to go home.
Although he is now feeling better, he is depressed about the state of his personal life, and is
drinking and smoking more than ever.
Three months later he starts experiencing symptoms of gastritis. He decides to buy antacids
over the counter from his local pharmacy. The pharmacist recommends an antacid that
combines aluminium and magnesium salts. The antacid works, and he starts to feel better.
16) Explain why antacids are beneficial in alleviating symptoms of gastritis.
17) Why are antacids that combine magnesium and aluminium salts better than those with either agent alone?
18) How are mucosal protective agents beneficial in the treatment of gastritis and gastric ulcers?
Over time Carter develops increasing abdominal discomfort and pain, which he is less able to
manage with antacids. He makes an appointment to see his GP. They have a frank discussion,
and the GP warns Carter that unless he modifies his lifestyle, it is likely that he will have to take
a proton pump inhibitor long term.
When Carter picks up his prescription, the pharmacist tells him to take the proton pump
inhibitor with breakfast, and to ensure that he swallows the tablet whole.
19) Explain why the proton pump inhibitor tablet should be swallowed whole.
20) What are the potential problems with long-term proton pump inhibitor use?

Chapter 13
Disorders of the lower
gastrointestinal tract
Useful terms for this topic
Enterocytes: Epithelial cells lining the intestines,
specialized for absorption.
Gastroenteritis: Inammation of the stomach and
intestinal walls typically resulting from bacterial or viral
infections, and causing vomiting and diarrhoea.
Irritable bowel syndrome: A common long-term
condition affecting the colon. Characterized by
abdominal pain, discomfort, and altering bowel habits.
Laxative: A drug that promotes emptying of the
bowels.
e two most commonly encountered disorders arising
from dysfunction of the lower gastrointestinal tract,
diarrhoea and constipation, are familiar to more or less
everybody at some point in their lives. ese conditions,
which can contribute signicantly to feelings of poor
health, are themselves symptoms rather than diseases,
arising from a number of causes. e two conditions can
be interrelated; for example, constipation can be the
cause of diarrhoea owing to irritants released from
stagnant faeces in the intestines. As patterns of bowel
movements vary enormously between individuals, these
conditions are diagnosed with reference to the
individual’s normal pattern.
Irritable bowel syndrome (IBS) is a common but
lessclearly diagnosed problem aecting the lower
gastrointestinal tract, specically the colon. It features
agroup of symptoms including both diarrhoea and
constipation, as well as frequent abdominal discomfort
and pain. e condition is considered further in
Workbook 10 at the end of this chapter, as our ctional
patient Helen suers such symptoms over a prolonged
period, and is diagnosed with IBS.
13.1 The lower gastrointestinal tract
e lower gastrointestinal tract refers to that section of the
digestive system from the small intestine through to
theanus. e function of the small intestine is to continue
the digestion of carbohydrates and proteins which began
in the stomach, and to digest fats. A number of hormones
regulate the release of secretions from accessory organs.
ese secretions enable the digestive process (see also
Introduction to Part 4).
• e pancreas releases enzymes that digest the three
primary categories of food: carbohydrates, proteins
andfats.
• e liver produces bile. is contains bile salts that act
as detergents to emulsify fats, breaking them into
smaller droplets, and facilitating their digestion by
pancreatic enzymes (lipases).
Once digestion is complete, the resulting small molecules
can be absorbed. is takes place largely in the
duodenum and jejunum regions of the small intestine,
where most of the ingested water, vitamins, and
electrolytes are also absorbed. (Some substances are
absorbed directly by the stomach, e.g. alcohol and some
drugs, including non-steroidal anti-inammatory drugs.)
Over the course of a day a huge volume of uid,
approximately 8–10 litres, enters the small intestine, of
which only around 2 litres is dietary in origin; the
remainder is derived from secretions (saliva, gastric

330 Chapter 13 Disorders of the lower gastrointestinal tract
OH
Box 13.1
Water absorption in the intestine
Blood vessel Enterocyte
Lumen of
intestine
1
+
K
+
Na
+
Na
SGLT1
2
Glucose
3
Glucose
4
H
2
Figure a
1. The Na+/K+-ATPase on the basolateral membrane actively pumps Na+ out of the cell,
against a concentration gradient (primary active transport).
2. A concentration gradient for Na+ is established, which favours the entry of Na+ into the cell.
This in turn drives the transport of glucose across the brush border of the epithelial cells
lining the small intestine. This secondary active transport is carried out by the sodium and
glucose co-transporter SGLT1. Na+ binds to the luminal side of the SGLT1 protein and
causes a conformational change, increasing its affinity for glucose, which is carried into the
cell against its concentration gradient. Na+ and glucose are thereby taken up by the
epithelial cells. Movement of additional ions, such as uptake of Cl–, is also favoured by the
Na+ concentration gradient (not shown).
3. A second glucose transporter GLUT-2, on the basolateral membrane of the intestinal
epithelial cells, allows diffusion of glucose out of the cell to enter the plasma. The glucose
travels along its concentration gradient by facilitated diffusion.
4. The resulting elevation in glucose and Na+ concentration to the capillary side of the
basolateral membrane creates a localized high osmotic pressure. This passively draws
water from the gut lumen across the cell, and into the plasma.
O
2
and pancreatic secretions, etc.). is uid must be
reabsorbed into the plasma across the wall of the small
intestine by specialized cells called enterocytes
(seeBox 13.1).
e mucosal layer of enterocytes is adapted for its role of
absorption in two broad ways.
1. e enterocytes possess a number of specialized
transport mechanisms responsible for the uptake
ofspecic molecules
2. e cells are arranged as tiny projections (villi) poking
into the lumen, which increase the surface area for
absorption. is is increased still further by even

13.2 Diarrhoea 331
smaller hair-like projections (microvilli/brush border)
on the luminal surface of each enterocyte. Together,
these modications increase the absorptive surface
area 600-fold.
Where the volume of uid absorbed does not match that
secreted (for instance, where a person is suering with
diarrhoea), dehydration, electrolyte depletion, and acid–
base imbalance can ensue.
13.2 Diarrhoea
Diarrhoea is a symptom rather than a disease, and can be
caused by numerous factors including an underlying
medical condition, as a side eect of drugs, or from a
psychological state such as anxiety. Most cases of diarrhoea
in Western countries, though, are the result of viral and
bacterial infections, notably Campylobacter (the most
common cause of food poisoning in the UK) and norovirus
in adults, and rotavirus in children. Gastroenteritis
describes the inammation of the stomach and intestinal
walls that can result from such infections.
e presence of an infectious agent in the gut causes local
irritation of the small intestine walls. is increases the
peristaltic action of the intestinal smooth muscles,
increasing the speed of transit of the gut contents and not
allowing enough time for absorption. rough a variety of
dierent mechanisms, pathogens increase secretions of
electrolytes and water into the small intestine, and some
also reduce absorption. Cholera toxin, for instance,
promotes secretion into the gut by stimulating adenylyl
cyclase activity in the intestinal epithelial cells. It does so
by causing a persistent activation of Gs subunits through
an inhibition of the inbuilt GTPase activity, which
ordinarily returns the subunit to its inactive state (see
Chapter 2, Section 2.2.4). e result is an increase in
cellular cyclic AMP levels which, through activation of
protein kinase A, massively increases the conductance of
Cl– into the gut lumen. Other diarrhoea-inducing
microbes act through other mechanisms to increase Cl–
secretion, or to reduce Na+ absorption. Importantly,
particularly in terms of therapy, microbes which induce
diarrhoea, including cholera toxin, do not aect SGLT-1
(see Box 13.1).
In Western countries nearly all cases of diarrhoea are
acute and self-limiting. Studies in these areas have
indicated that around 5–7% of people report having had
diarrhoea in the previous 4 weeks, with the greatest
prevalence amongst the youngest (almost 1 in 10 children
e volume of gut contents normally reaching the large
intestine is around 500 ml. is is made up of indigestible
food residues, excreted substances (e.g. certain drugs),
and some water. e role of this section of the digestive
tract is to further remove water and salt, and to compact
the contents to form faeces for elimination. If the waste is
retained for a prolonged period in the large intestine, too
much water may be removed, resulting in constipation.
under 5 years); these same studies found that only 1 in 5
seek medical care. In developing countries, however,
diarrhoea can be chronic and/or life-threatening;
diarrhoea-inducing infections, mostly contracted by
drinking contaminated water, are one of the leading
causes of infant death, as a result of dehydration.
Alternatively, diarrhoea can be caused by the presence of
non-absorbable substances in the digestive tract lumen
creating an osmotic gradient, which draws water into the
gut and retains it there (osmotic diarrhoea). is arises in
lactose-intolerant individuals, where a deciency in the
enzyme lactase leads to undigested lactose remaining in
the intestine. It is also how diarrhoea is caused by antacid
treatment with magnesium salts (see Chapter 12, Section
12.4.1), or by excessive consumption of foods containing
articial sweeteners (e.g. xylitol and mannitol). When the
causative agent is no longer present, the condition
generally resolves.
Diarrhoea is diagnosed with reference to a person’s
normal bowel habits. e clinical diagnosis of diarrhoea
is increased frequency of watery or liquid stools, often
with a stool mass above 200 g per day. Where the
condition continues beyond 14 days, it is classied as
persistent. If blood is present, a diagnosis of dysentery is
made; this is usually caused by a bacterial, protozoan, or
parasitic infection.
13.2.1 Treatment of diarrhoea
Mild to moderate gastroenteritis is usually self-limiting,
lasting only 24–48 hours. Aected individuals should
maintain adequate uid intake to compensate for water
and electrolyte loss. Very young and frail elderly patients
are at particular risk of dehydration, and this can mean
that even moderate diarrhoea is potentially lifethreatening. Where dehydration is a danger, oral
rehydration therapy is recommended to prevent, or
reverse, depletion of uid and electrolytes.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
